Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: TUBA4A

Summary for TUBA4A

Gene information	Gene symbol	TUBA4A
	Ensembl ID	ENSG00000127824
	Entrez ID	7277
	Gene name	tubulin alpha 4a
	Synonyms	FLJ30169\|H2-ALPHA\|TUBA1
	Gene type	protein_coding
	UniProtAcc	P68366

Top

Dataset with differentially expressed gene: TUBA4A

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-1.66709	3.57e-11
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.451401	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.969209	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.459358	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.287758	3.46e-04
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.698557	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.291636	3.53e-41
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.30375	1.81e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.523032	1.63e-29
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.827467	1.79e-12
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	-0.508505	5.06e-03
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.1202	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.523717	1.81e-27
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.393005	1.53e-07
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.364857	3.14e-15
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD8+ T cells	0.325975	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.318819	1.45e-12
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.466839	2.02e-15
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.328706	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.428927	1.29e-18
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.382476	1.13e-33
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.452533	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-1.12677	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.784051	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.278415	5.20e-19
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.265004	1.15e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.370378	7.67e-03
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.616701	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.756529	0.00e+00
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.613195	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.537004	1.22e-28
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.265037	3.79e-20
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.317841	2.30e-29
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.45406	2.85e-30

Top

Expression of TUBA4A in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to TUBA4A

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating TUBA4A

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
TUBA4A	hsa-miR-450b-5p	94.5042	NM_001278552
TUBA4A	hsa-miR-3202	90.6191	NM_006000
TUBA4A	hsa-miR-520a-5p	86.7826	NM_001278552
TUBA4A	hsa-miR-525-5p	86.7826	NM_001278552
TUBA4A	hsa-miR-6838-5p	85.7934	NM_001278552
TUBA4A	hsa-miR-15a-5p	85.7934	NM_001278552
TUBA4A	hsa-miR-16-5p	85.7934	NM_001278552
TUBA4A	hsa-miR-195-5p	85.7934	NM_001278552
TUBA4A	hsa-miR-15b-5p	85.7934	NM_001278552
TUBA4A	hsa-miR-424-5p	85.5237	NM_001278552
TUBA4A	hsa-miR-497-5p	85.5237	NM_001278552

Page: 1

Top

Motifs and transcription factors (TFs) regulating TUBA4A

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
TUBA4A	transfac_pro__M06273	ZNF766 (directAnnotation).
TUBA4A	transfac_pro__M05507	IKZF3 (directAnnotation).
TUBA4A	taipale_tf_pairs__GCM1_ELF1_NRCCCRNNCGGAAGNN_CAP_repr	ELF1; GCM1 (directAnnotation).
TUBA4A	transfac_pro__M06751	ZNF510 (directAnnotation).
TUBA4A	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
TUBA4A	taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP	ETV5; FOXI1 (directAnnotation).
TUBA4A	taipale_tf_pairs__ETV5_EVX1_RSCGGWAATKR_CAP	ETV5; EVX1 (directAnnotation).
TUBA4A	taipale_tf_pairs__FOXO1_ETV4_RCCGGAWGTKKN_CAP	ETV4; FOXO1 (directAnnotation).
TUBA4A	transfac_pro__M05981	ZNF233 (directAnnotation).
TUBA4A	kznf__ZNF805_Imbeault2017_RP_RCADE	ZNF805 (directAnnotation).
TUBA4A	hocomoco__SOX9_HUMAN.H11MO.1.B	SOX9 (directAnnotation).
TUBA4A	tfdimers__MD00270	DBX2; HMGA1; HMGA2 (directAnnotation).
TUBA4A	taipale_tf_pairs__TEAD4_HOXA13_GGWATGNNNRTAAA_CAP_repr	HOXA13; TEAD4 (directAnnotation).
TUBA4A	tfdimers__MD00432	DBP; STAT1 (directAnnotation).
TUBA4A	transfac_public__M00040	ATF2 (directAnnotation).
TUBA4A	transfac_pro__M05785	ZNF48 (inferredBy_Orthology).
TUBA4A	transfac_pro__M05561	HIC2 (inferredBy_Orthology).
TUBA4A	cisbp__M01815	CEBPE (inferredBy_Orthology).
TUBA4A	metacluster_46.4	CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; DBP; DBP; EP300; GATAD2A; HES2 (directAnnotation). CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; HLF; HLF (inferredBy_Orthology).
TUBA4A	hdpi__FLI1	FLI1 (directAnnotation).
TUBA4A	swissregulon__hs__ZNF691	ZNF691 (directAnnotation).
TUBA4A	taipale_tf_pairs__TEAD4_ERG_RSCGGAAATRCC_CAP	ERG; TEAD4 (directAnnotation).
TUBA4A	metacluster_22.19	NFE2 (directAnnotation).
TUBA4A	transfac_pro__M06115	ZNF28 (directAnnotation).
TUBA4A	metacluster_141.2	E2F2; E2F3 (directAnnotation).
TUBA4A	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
TUBA4A	transfac_pro__M06741	ZNF70 (directAnnotation).
TUBA4A	metacluster_22.28	BACH1 (directAnnotation).
TUBA4A	metacluster_22.34	BACH2 (directAnnotation).
TUBA4A	tfdimers__MD00085	MYB (directAnnotation).
TUBA4A	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
TUBA4A	metacluster_195.2	EGR2; KLF10; KLF10; KLF11; KLF11; KLF11; KLF13; KLF13; KLF13; KLF13; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF15; KLF15; KLF16; KLF3; KLF8; KLF9; KLF9; KLF9; SP1; SP1; SP1; SP3; SP3; SP4; SP8; SP8; SP8; SP9; SP9 (directAnnotation). EGR1; KLF1; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF2; KLF3; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF9; SP1; SP3; SP4; SP4; SP5; SP5; SP5; SP6; SP7; SP8; SP9 (inferredBy_Orthology).
TUBA4A	transfac_pro__M02082	ISL2 (directAnnotation).
TUBA4A	transfac_public__M00240	NKX2-5 (directAnnotation).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
TUBA4A	"Cabazitaxel"	DB06772	small molecule
TUBA4A	"CYT997"	DB05147	small molecule
TUBA4A	"Epothilone D"	DB01873	small molecule
TUBA4A	"Patupilone"	DB03010	small molecule
TUBA4A	"Phenethyl Isothiocyanate"	DB12695	small molecule
TUBA4A	"Podofilox"	DB01179	small molecule
TUBA4A	"Vincristine"	DB00541	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."